Compare ONTF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTF | PRLD |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 312.2M |
| IPO Year | 2021 | 2020 |
| Metric | ONTF | PRLD |
|---|---|---|
| Price | $8.11 | $3.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.10 | $5.67 |
| AVG Volume (30 Days) | ★ 986.7K | 298.3K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.67 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $139,312,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $1.51 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $4.70 | $0.75 |
| 52 Week High | $8.11 | $5.54 |
| Indicator | ONTF | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 45.88 |
| Support Level | $7.84 | $3.92 |
| Resistance Level | N/A | $4.10 |
| Average True Range (ATR) | 0.02 | 0.31 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 88.89 | 46.49 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.